The observation that splenic erythroid cells can overcome ATPIF1 deficiency via glycolytic/PPP activation suggests that pharmacological agents targeting these pathways (e.g., PPP activators like metformin or glycolytic enhancers) could mitigate anemia in patients with mitochondrial dysfunction. Here, ATP5IF1 is linked to anemia (phenotype).